In addition to in vitro studies, in vivo experiments using stable A172 cells demonstrated a reduction in tumor growth when TXNDC12 expression was modulated, further supporting the idea that inducing oxidative stress through TXNDC12 manipulation can be a viable strategy for treating glioblastoma [103]. This evidence concerns the gene TXNDC12 and glioblastoma.